Home » Stocks » RSLS

ReShape Lifesciences Inc. (RSLS)

Stock Price: $4.52 USD -0.77 (-14.56%)
Updated May 7, 2021 2:57 PM EDT - Market closed
Market Cap 32.68M
Revenue (ttm) 11.30M
Net Income (ttm) -21.63M
Shares Out 6.93M
EPS (ttm) -3.12
PE Ratio n/a
Forward PE n/a
Dividend n/a
Dividend Yield n/a
Trading Day May 7
Last Price $4.52
Previous Close $5.29
Change ($) -0.77
Change (%) -14.56%
Day's Open 4.15
Day's Range 4.15 - 4.52
Day's Volume 506
52-Week Range 1.51 - 11.50

News

Hide News
  • All
  • Videos
  • Press Releases
  • Conversation

SAN CLEMENTE, CA / ACCESSWIRE / March 10, 2021 / ReShape Lifesciences Inc. (OTCQB:RSLS), a global weight-loss solutions leader, today reported financial and operational results for the fourth quarter an...

2 months ago - Accesswire

Webinar to discuss results on March 10, 2021 at 4:30 p.m. E.T SAN CLEMENTE, CA / ACCESSWIRE / March 8, 2021 / ReShape Lifesciences Inc. (OTCQB:RSLS), a leading developer and distributor of minimally inv...

2 months ago - Accesswire

ReShape Lifesciences' (RSLS) CEO Bart Bandy on Q3 2019 Results - Earnings Call Transcript

1 year ago - Seeking Alpha

ReShape Lifesciences Inc. (RSLS) CEO Bart Bandy on Q2 2019 Results - Earnings Call Transcript

1 year ago - Seeking Alpha

ReShape Lifesciences Inc. (RSLS) CEO Bart Bandy on Q1 2019 Results - Earnings Call Transcript

1 year ago - Seeking Alpha

ReShape Lifesciences Inc.'s (RSLS) CEO Dan Gladney on Q4 2018 Results - Earnings Call Transcript

2 years ago - Seeking Alpha

About RSLS

ReShape Lifesciences Inc., a medical device company, provides products and services that manages and treat obesity and metabolic diseases in the United States, Australia, Europe, and internationally. The company's product portfolio includes Lap-Band System, a minimally invasive long-term treatment of severe obesity and more invasive surgical stapling procedures, such as the gastric bypass or sleeve gastrectomy; and ReShape Vest system, an investigational, minimally invasive, laparoscopically implanted medical device that wraps around the stomac... [Read more...]

Industry
Medical Devices
IPO Date
Nov 15, 2007
CEO
Barton Bandy
Employees
37
Stock Exchange
OTCMKTS
Ticker Symbol
RSLS
Full Company Profile

Financial Performance

In 2020, RSLS's revenue was $11.30 million, a decrease of -25.12% compared to the previous year's $15.09 million. Losses were -$21.63 million, -70.85% less than in 2019.

Financial Statements